DEPRESSION: THE HIDDEN TOLL OF PARKINSON'S DISEASE

When many picture Parkinson's disease, they think of trembling hands and shuffling gait, the slow, deliberate movements that are the disease's most visible hallmarks. What they don't picture is depression—and that blind spot may be costing patients.

Depression affects roughly half of all people living with Parkinson's disease. “The data and quality of life research shows that depression has an equal—and sometimes greater—effect on daily life than the motor symptoms,” says Salih Cayir, MD, a Yale School of Medicine (YSM) postdoctoral associate and incoming psychiatry resident at the University of Texas Health Science Center at Houston.

6Yet depression in Parkinson's has long been understudied, underdiagnosed, and undertreated. Part of the reason is a stubborn assumption: that if a patient is depressed, it's probably a natural response to a difficult diagnosis. Treat the Parkinson's, manage the tremors, and the mood will follow.

A new Yale-led study published in Brain Communications challenges that assumption at a biological level—and in doing so, points toward a new generation of treatments that could change how the disease is managed.

The study used a specialized brain imaging technique called SV2A PET to measure synaptic density—essentially, the number of active communication connections between neurons. They focused on three groups: patients with Parkinson's who had depression, those without depression, and healthy controls.

Synapses are the junctions where one neuron hands off a signal to another. When synapses are lost, that hand-off breaks down. In Parkinson's, it's well established that synaptic loss in the brain's motor circuits causes movement problems. What nobody had directly shown, until now, is what happens to synapses in the parts of the brain that regulate mood.

What makes SV2A PET particularly powerful is its breadth. "It picks up all synapses," explains David Matuskey, MD, associate professor of psychiatry and radiology at YSM and one of the study’s co-authors. "It doesn't matter if it's dopamine or a different neurotransmitter. It really is just like a big picture." That's a meaningful distinction from other imaging tools, which tend to target specific chemical systems.

Despite these encouraging results, researchers caution that the model has limitations. It was evaluated retrospectively using benchmark datasets rather than prospective clinical trials. It also focused only on distinguishing Parkinson’s patients from healthy controls, without assessing disease stages or subtypes. Additionally, real-world variability — such as differences in recording conditions — remains a challenge.

Even so, this research represents an important step forward. By merging multiple digital biomarkers into a transparent, interpretable AI framework, scientists are moving closer to reliable, scalable Parkinson’s screening tools. With further validation and clinical collaboration, such systems could one day support earlier diagnosis, guide treatment decisions, and ultimately improve outcomes for people living with Parkinson’s.

The results were striking—and, to the researchers, partly unexpected. Patients with Parkinson's disease who had symptoms of depression showed significantly lower synaptic density than both the non-depressed patients with Parkinson’s and healthy controls in four key mood-regulating hubs: the dorsolateral prefrontal cortex, the anterior cingulate cortex, the amygdala, and the hippocampus. The results showed that the more severe a patient's depression, the lower their synaptic density in those regions. At the same time, motor symptom severity tracked with synaptic loss in an entirely different part of the brain—the substantia nigra, the region long associated with Parkinson's motor decline. "We observed this coupling and decoupling between mood and motor circuitry when it comes to depressive and motor symptoms," says Cayir, who is the study's lead author. "For me, that was the most interesting finding in the study." In other words, depression in Parkinson's isn't simply a side effect of feeling ill—it has its own distinct biological signature.

That finding carries immediate practical implications, starting with why the standard treatments for depression don't work very well for patients with Parkinson’s disease.

Most antidepressants prescribed today target the brain's serotonin system. They're reasonably effective for depression in the general population, but studies consistently show they have limited efficacy in patients with Parkinson's. The new findings may explain why: the drugs don't address synaptic loss.

"We need to understand the mechanism so we can target the actual causes of depression in Parkinson's," says Sophie Holmes, PhD, assistant professor of psychiatry at Yale School of Medicine and senior of the study. "Traditional antidepressants are probably not targeting the underlying mechanisms.“

If the problem is a loss of synaptic connections in mood circuitry, the logical response is to look for treatments that can rebuild those connections—a process called synaptogenesis. Several candidates are emerging.

Ketamine, the fast-acting anesthetic that has gained attention as a rapid antidepressant, is thought to work by restoring synaptic connections lost to stress and depression. Holmes’ team, co-led with Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry at YSM, has recently completed a clinical trial showing that ketamine produced significant antidepressant effects compared with placebo in patients with Parkinson’s disease and depression—results that will be published soon.

Another trial examining psilocybin, the active compound in psychedelic mushrooms, is now open for enrollment. Co-led by Holmes and Sanacora, the study will use SV2A PET imaging and MRI to determine whether psilocybin can restore synaptic deficits within the neural circuits implicated in this work.

There may also be a lower-tech option. Exercise, Holmes notes, is currently the only intervention proven to slow Parkinson's disease progression—and it's also one of the most powerful drivers of synaptic plasticity. “Exercise has profound effects on mental health,” she says. “Some of these effects may arise from enhancing synaptic plasticity within mood-related brain circuits identified in this study.”

The study also reflects something larger happening in neuroscience: a continuing unification of neurology and psychiatry.

"I joke with medical students that this is the only instance where there are two specialties and one organ," says Matuskey, who trained as a neuropsychiatrist. "There is no neurological and psychiatric part of the brain. It's just the brain."

Depression in Parkinson's disease has historically fallen through the gap between the two fields—a problem for both neurologists who focus on movement and psychiatrists who weren't trained in Parkinson's. “But if you talk to people with Parkinson's disease, it's not a gap at all,” Matuskey adds. “It's one of the main drivers of the problem.”